Earnings

UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate

Nov 3, 2026 · 06:02 PM ET· updated 46m ago

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.53) by 20.75 percent. This is a 13.51 percent increase over losses of $(0.74) per share

Why It Matters

Denali lost more money per share than experts thought it would. But the company sold way more product than people expected.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DNLI20.48

+1.62 (+8.59%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.